Condition: Leukemia/Lymphoma · Cutaneous T Cell Lymphoma · ATLL · Sponsor: Kyowa Kirin, Inc.
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
This description comes directly from the study's public registry record.
Linda J Burns, MD · 414-805-0714 · lburns@mcw.edu
Jatin Jadwani, BDS, MSc Clinical Research · +49 15114861167 · jatin.jadwani@kyowakirin.com
Always discuss trial participation with your own doctor first.
| CIBMTR | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04014374